The beneficial effect of blocking Kv1.3 in the psoriasiform SCID mouse model

Journal of Investigative Dermatology

Volumn 131, Issue 1, 2011, Pages 118-124

  Gilhar, Amos ^a   Bergman, Reuven ^b   Assay, Bedia ^a   Ullmann, Yehuda ^a   Etzioni, Amos ^a  

^a TECHNION ISRAEL INSTITUTE OF TECHNOLOGY   (Israel)

^b RAMBAM MEDICAL CENTER   (Israel)

Author keywords

[No Author keywords available]

Indexed keywords

HERBACEOUS AGENT; NEUROTOXIN; POTASSIUM CHANNEL KV1.3; STICHODACTYLA HELIANTHUS NEUROTOXIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE MARKER; HUMAN; MOUSE; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PSORIASIS; SKIN GRAFT; XENOGRAFT;

EID: 78650287424     PISSN: 0022202X     EISSN: 15231747     Source Type: Journal    
DOI: 10.1038/jid.2010.245     Document Type: Article

References (24)

1. v1.3 blocker PAP-1 suppresses allergic contact dermatitis. J Invest Dermatol 127:1419-29
2. Beeton C, Barbaria J, Giraud P et al. (2001a) Selective blocking of voltage-gated K+ channels improves experimental autoimmune encephalomye-litis and inhibits T cell activation. J Immunol 166:936-44
3. v1.3 channels for therapy of autoimmune diseases. Mol Pharmacol 6:1369-81
4. + channels and inhibits T lymphocyte proliferation. J Biol Chem 283:988-97
5. + channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis. Proc Natl Acad Sci USA 98:13942-7
6. v1.3 channels are a therapeutic target for T cell-mediated autoimmune diseases. Proc Natl Acad Sci USA 103:17414-9
7. Biedermann T, Kneilling M, Mailhammer R et al. (2000) Mast cells control neutrophil recruitment during T cell-mediated delayed-type hypersensi-tivity reactions through tumor necrosis factor and macrophage inflammatory protein 2. J Exp Med 192:1441-52
8. + channels as targets for specific immunomodulation. Trends Pharmacol Sci 25:280-9
9. Ellis C, Krueger GG (2001) Alefacept clinical study group. N Engl J Med 345:248-55
10. Gilhar A, Ullmann Y, Kerner H et al. (2002) Psoriasis is mediated by a cutaneous defect triggered by activated immunocytes: induction of psoriasis by cells with natural killer receptors. J Invest Dermatol 119:384-91
11. Gilhar A, Yaniv R, Assy B et al. (2006) Fas pulls the trigger on psoriasis. Am J Pathol 168:170-5
12. Koo GC, Blake JT, Shah K et al. (1999) Correolide and derivatives are novel immunosuppressants blocking the lymphocyte Kv1.3 potassium channels. Cell Immunol 197:99-107
13. v1.3 channel block. Immunity 29:602-14
14. Nickoloff BJ, Kunkel SL, Burdick M et al. (1995) Severe combined immunodeficiency mouse and human psoriatic skin chimeras. Validation of a new animal model. Am J Pathol 146:580-8
15. Nickoloff BJ, Wrone-Smith T, Bonish B et al. (1999) Response of murine and normal human skin to injection of allogeneic blood- derived psoriatic immunocytes: detection of T cells expressing receptors typically present on natural killer cells, including CD94, CD158, and CD161. Arch Dermatol 135:546-52
16. Norton RS, Pennington MW, Wulff H (2004) Potassium channel blockade by the sea anemone toxin ShK for the treatment of multiple sclerosis and other autoimmune diseases. Curr Med Chem 11:3041-52
17. v1.3 potassium channels are localized in the immunological synapse formed between cytotoxic and target cells. Proc Natl Acad Sci USA 101:1285-90
18. Pennington M, Mahnir V, Krafte D et al. (1996) Identification of three separate binding sites on ShK toxin, a potent inhibitor of voltage-dependent potassium channels in human T-lymphocytes and rat brain. Biochem Biophys Res Commun 219:696-701
19. Raychaudhuri SP, Raychaudhuri SK, Wulff H (2009) The voltage-gated potassium channel Kv1.3 in psoriasis and psoriatic arthritis: a therapeutic target for T cell-mediated autoimmune diseases. Arthritis Rheum 60(Suppl 10):1434 (abstract)
20. Rus H, Pardo CA, Hu L et al. (2005) The voltage- gated potassium channel Kv1.3 is highly expressed on inflammatory infiltrates in multiple sclerosis brain. Proc Natl Acad Sci USA 102:11094-9
21. Valverde P, Kawai T, Taubman M (2004) Selective blockade of voltage-gated potassium channels reduces inflammatory bone resorption in experimental periodontal disease. J Bone Miner Res 19:155-64
22. Wang B, Zhuang L, Fujisawa H et al. (1999) Enhanced epidermal Langerhans cell migration in IL-10 knockout mice. J Immunol 62:277-83
23. Wulff H, Beeton C, Chandy KG (2003a) Potassium channels as therapeutic targets for autoimmune disorders. Curr Opin Drug Discov Devel 6:640-7
24. + channel in effector memory T cells as new target for MS. J Clin Invest 111:1703-13